InnoTech Precision Medicine
Democratizing Early Cancer Detection

Cancer diagnostics is overdue for innovation, particularly in the area of oral and nasal, aka head and neck cancer. InnoTech Precision Medicine is meeting this need with Recognize™, a cutting-edge patented and pending diagnostic platform designed to make earlystage cancer detection easier, more precise and accessible.

Moving away from invasive biopsies, Recognize™ employs liquid biopsy technology using a simple saliva sample. The platform identifies cancer predisposition, and progression markers simultaneously and integrates these results with patient history using artificial intelligence.

Few other technologies only utilize genomic or cancer progression markers for detection. Genetic predisposition alone does not guarantee disease manifestation; progression markers are needed to express genetic material.

InnoTech’s breakthrough technology analyzes genes, their copies and protein markers precisely, delivering a comprehensive diagnostic profile. This advanced approach provides precise insights into the likelihood of cancer development and its current stage of progression, exceeding the capabilities of existing methods.

“Early detection can mean the difference between manageable treatment and severe outcomes that drastically affect quality of life,” says Dr. Roya Khosravi-Far, co-founder and CEO. “Recovery and survival rates are significantly higher when the diagnosis is made at early stage of cancer.”

oral cancer is typically screened through visual assessments, leading to invasive biopsies that may already signal late-stage cancer. Over 50 percent of oral cancers are diagnosed at later stages, with survival rates dropping below 30 percent for stage IV. At this stage, treatment often requires life-altering surgeries that impact speech, swallowing and overall quality of life.

InnoTech’s approach challenges this reality by integrating advanced multiomics technology to detect early signs of cancer. Saliva is collected using its collection kit and placed in a disposable test cartridge containing specific reagents to simultaneously test multiplex of different classes of disease biomarkers for head and neck cancer. The result appears within minutes on an app.

“This makes the patient journey extremely simple, user-friendly and actionable,” says Ms. Mariya Filipova, Managing Director, The 4100 Group. “Precise early detection also reduces overall healthcare costs by shifting the focus from expensive, late-stage diagnostics to less costly and potentially curative treatments.”

The innovation lies not only in its technology but also in its simplicity and accessibility. The Recognize™ device, no larger than an Alexa Echo, empowers healthcare providers to test for HPV-related cancers—common causes of oral, head, and neck cancers—on-site without the delays of mailing samples to labs and removing the need for additional office visits. Patients and providers benefit from the immediacy and reliability of this groundbreaking tool, setting a new standard in cancer diagnostics.

Early detection can mean the difference between manageable treatment and severe outcomes that drastically affect quality of life

While healthcare innovation often faces challenges in scaling and adoption, InnoTech has designed its solution with practicality and ease of integration in mind. Recognize™ is portable, cost-effective and intuitive, ensuring its feasibility for deployment in dental offices, primary care clinics and mobile units. The device’s affordability allows practices to integrate multiple units, even in underresourced settings.

This deliberate design aligns with InnoTech’s commitment to ensuring advanced diagnostics are accessible to underserved populations, including those at higher risk due to smoking, lifestyle, limited healthcare access, or family history. Removing barriers to adoption and focusing on scalability, InnoTech is setting the stage for broader implementation.

InnoTech’s technology is transformative beyond its initial focus on oral cancer, representing a platform for broader applications. The advanced chemistry of the Recognize™ platform enables the creation of disease-specific cartridges, broadening InnoTech’s impact across diverse healthcare applications.

The company’s journey, built on a robust foundation of research funded mainly through grants, showcases its commitment to scientific rigor and quality. With rigorous lab testing complete, InnoTech is preparing for FDA approval within the next 24 months, with a market launch anticipated in 2027. The rollout strategy is equally thoughtful, beginning with oral surgeons, ENTs and periodontists to replace invasive biopsies before expanding to dentists and primary care providers for routine screenings, reflecting its vision to transform healthcare delivery.

Shifting the focus from reactive treatments to proactive prevention, InnoTech is redefining what’s possible in cancer diagnostics.